Molecular Mechanisms and Therapeutic Targets of RNA-Based and Traditional Lipid-Lowering Agents in Residual Cardiovascular Risk: A Scoping Review of Key Directions Towards Future Perspectives
Biomolecules · 29.05.2026 · 16 (6) · 807
DOI: 10.3390/biom16060807 ↗Kurz gefasst
Scoping Review in der Zeitschrift Biomolecules, online erschienen am 29.05.2026. Verfasst von Diana Tatarciuc und 10 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania. Hauptthemen laut MEDLINE: Cardiovascular Diseases, RNA, Small Interfering, Hypolipidemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Residual cardiovascular risk arises from dysregulated expression of genes encoding apolipoprotein(a) (LPA), apolipoprotein C-III (APOC3), angiopoietin-like gene 3 (ANGPTL3), and proprotein convertase subtilisin/kexin type 9 (PCSK9). RNA-based therapies, small interfering RNAs (siRNAs), and antisense oligonucleotides (ASOs) modulate these targets at the post-transcriptional level through RNA interference and RNase H-mediated degradation, respectively. This scoping review maps the molecular mechanisms, target involvement, and pharmacodynamic outcomes of RNA therapies for managing residual cardiovascular risk, with contextual comparison to traditional lipid-lowering agents. A systematic search of PubMed, Embase, Web of Science, and Scopus was performed from 2020 to February 2026. Of the 1088 records identified, 30 studies met the inclusion criteria. RNA therapies have demonstrated potential for engagement, with 80–98% reductions in Lp(a) (pelacarsen, olpasiran, zerlasiran, lepodisiran), 50–80% reductions in triglycerides (olezarsen, plozasiran, volanesorsen), and 36–44% reductions in low-density lipoprotein cholesterol (LDL-C). Mechanistically, siRNAs achieve gene silencing through RISC-mediated mRNA cleavage, with sustained pharmacodynamic effects (3–6 months) because of Argonaute-2 stability, while gapmer ASOs recruit RNase H1 for mRNA degradation. Conjugation with GalNAc allows for hepatocyte-specific delivery with a subcutaneous bioavailability of 70–85%. Safety profiles were favorable, with injection site reactions (4–12%) being the most common adverse event. This analysis maps the emerging molecular landscape of RNA therapies, highlighting their substantial precision for targeting residual cardiovascular risk pathways that cannot be addressed by traditional agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.
ORCID-Profile: Ana Maria Raluca Pauna, Adina Oana Armencia, Dragos Catalin Ghica, Ovidiu Stamatin, Roxana Ionela Vasluianu
Zitieren
APA
Tatarciuc, D., Esanu, I. M., Trandafirescu, M. F., Pauna, A. M. R., Vasilcu, T. F., Foia, I., Armencia, A. O., Antohe, M. E., Ghica, D. C., Stamatin, O., & Vasluianu, R. I. (2026). Molecular Mechanisms and Therapeutic Targets of RNA-Based and Traditional Lipid-Lowering Agents in Residual Cardiovascular Risk: A Scoping Review of Key Directions Towards Future Perspectives. Biomolecules, 16(6), 807. https://doi.org/10.3390/biom16060807
Vancouver
Tatarciuc D, Esanu IM, Trandafirescu MF, Pauna AMR, Vasilcu TF, Foia I, et al. Molecular Mechanisms and Therapeutic Targets of RNA-Based and Traditional Lipid-Lowering Agents in Residual Cardiovascular Risk: A Scoping Review of Key Directions Towards Future Perspectives. Biomolecules. 2026;16(6):807. doi:10.3390/biom16060807
BibTeX
@article{Tatarciuc2026,
author = {Tatarciuc, Diana and Esanu, Irina Mihaela and Trandafirescu, Mioara Florentina and Pauna, Ana Maria Raluca and Vasilcu, Teodor Flaviu and Foia, Iolanda and Armencia, Adina Oana and Antohe, Magda Ecaterina and Ghica, Dragos Catalin and Stamatin, Ovidiu and Vasluianu, Roxana Ionela},
title = {Molecular Mechanisms and Therapeutic Targets of RNA-Based and Traditional Lipid-Lowering Agents in Residual Cardiovascular Risk: A Scoping Review of Key Directions Towards Future Perspectives},
journal = {Biomolecules},
year = {2026},
volume = {16},
number = {6},
pages = {807},
doi = {10.3390/biom16060807}
}
EUVIMED